甲状腺がん治療薬市場：薬剤タイプ、投与方法、病期、がんタイプ、エンドユーザー別-2025-2030年の世界予測

甲状腺がん治療薬市場は、2023年に8億601万米ドルと評価され、2024年には8億9,096万米ドルに達すると予測され、CAGR 11.02%で成長し、2030年には16億7,577万米ドルに達すると予測されています。

甲状腺がん治療薬市場の範囲には、低分子阻害剤、免疫療法、放射性ヨード治療、甲状腺ホルモン療法など、甲状腺がんを治療するために特別に設計された医薬品が含まれます。甲状腺がんの罹患率の増加により、効果的な治療法の必要性が強調されているため、この分野はアンメット・メディカル・ニーズに対応する上で極めて重要です。これらの薬剤は、乳頭がん、濾胞がん、髄様がん、未分化がんなど、さまざまなタイプの甲状腺がんの管理や治癒を目指す医療専門家によって、主に臨床の場で適用されます。最終用途には、病院、腫瘍センター、がん治療専門のクリニックなどが含まれます。この市場の主な成長要因としては、精密医療や標的治療の進歩、研究開発投資の増加、患者の意識の高まりや効果的な治療オプションに対する需要などが挙げられます。バイオシミラーの出現と創薬におけるAIの統合は、より個別化された医療と費用対効果の高い治療への道を開く潜在的な機会です。こうした機会を活用するため、製薬企業は強固な研究開発プログラムや戦略的パートナーシップに投資して医薬品開発を加速し、規制当局の承認を合理化する必要があります。しかし、市場は、高い開発コスト、厳しい規制の枠組み、甲状腺がん治療に伴う潜在的な副作用などの制約に直面しています。さらに、薬物療法よりも手術を選択する患者もいるため、外科的治療法との競合も課題となっています。技術革新の面では、新規分子標的の開発、ドラッグデリバリーシステムの改善、併用療法の探求といった分野が、事業成長の大きな機会となっています。市場はダイナミックであるが、高い競合と規制のハードルという制約があるため、競争力を維持し世界市場での足場を確保するためには、戦略的計画と継続的なイノベーションが必要となります。

市場力学：急速に進化する甲状腺がん治療薬市場の主要市場インサイトを公開

甲状腺がん治療薬市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。こうした動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 世界中で増加する甲状腺がんの有病率
  • 早期診断と治療への注目の高まり
  • 民間団体によるがん検診プログラムの増加
• 市場抑制要因
  • 甲状腺がん治療に伴う副作用
• 市場機会
  • がんに対する認識向上と償還政策の導入を促進する政府の好意的な取り組み
  • 個別化医療と標的治療の潜在的可能性の拡大
• 市場の課題
  • 政府の厳しい医薬品承認手続き

ポーターの5つの力：甲状腺がん治療薬市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：甲状腺がん治療薬市場における外部からの影響の把握

外部マクロ環境要因は、甲状腺がん治療薬市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析甲状腺がん治療薬市場における競合情勢の把握

甲状腺がん治療薬市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス甲状腺がん治療薬市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、甲状腺がん治療薬市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によりベンダーを明確かつ的確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨甲状腺がん治療薬市場における成功への道筋を描く

甲状腺がん治療薬市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を検討することで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界中で甲状腺がんの罹患率が増加
    • 早期診断と治療への重点化
    • がん検診プログラムを増やす民間団体の増加
  • 抑制要因
    • 甲状腺がん治療に伴う副作用
  • 機会
    • がん啓発と保険償還政策のイントロダクションを促進する政府の好ましい取り組み
    • 個別化医療と標的療法の指数関数的可能性
  • 課題
    • 厳格な政府の医薬品承認手続き
• 市場セグメンテーション分析
  • 薬剤の種類：標的治療薬の採用が急増し、副作用の減少による患者の転帰の改善に直接つながっている
  • エンドユーザー：先進的な設備のおかげで病院全体で甲状腺がん治療薬の利用が進化
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 甲状腺がん治療薬市場薬の種類別

• 化学療法薬
• ホルモン療法薬
• 免疫療法薬
• 標的治療薬

第7章 甲状腺がん治療薬市場投与方法別

• 注射薬
• 静脈内投与薬
• 経口薬

第8章 甲状腺がん治療薬市場病気の段階別

• 進行期甲状腺がん
• 甲状腺がんの初期段階

第9章 甲状腺がん治療薬市場がんの種類別

• 未分化甲状腺がん
• 濾胞性甲状腺がん
• 甲状腺髄様がん
• 甲状腺乳頭がん

第10章 甲状腺がん治療薬市場：エンドユーザー別

• 病院
• 腫瘍科クリニック
• 調査機関

第11章 南北アメリカの甲状腺がん治療薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第12章 アジア太平洋地域の甲状腺がん治療薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第13章 欧州・中東・アフリカの甲状腺がん治療薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第14章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • FDA、RET変異甲状腺がんの若年患者にセルペルカチニブを承認、治療選択肢を拡大
  • 小野薬品工業、甲状腺がん治療における有望な進歩を発表
  • リゲル・ファーマシューティカルズがガヴレトの米国での権利を獲得、甲状腺がん治療の選択肢を拡大
• 戦略分析と提言

企業一覧

• Abbott Ltd.
• Aprazer Healthcare Pvt Ltd.
• AstraZeneca PLC
• Bayer AG
• Biovista Inc.
• Bristol Myers Squibb
• Dr Reddy's Laboratories Ltd.
• Eisai Co., Ltd.
• Eli Lilly and Company
• Exelixis Inc.
• GlaxoSmithKline PLC
• Glenmark Pharmaceuticals Ltd.
• Hetero Healthcare Limited
• Loxo Oncology Inc.
• Lupin Limited
• Merck & Co., Inc.
• MSN Laboratories
• Mylan N.V.
• Natco Pharma Ltd.
• Novartis AG
• Sanofi S.A.
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.
• Vascular Biogenics Ltd.

LIST OF FIGURES

• FIGURE 1. THYROID CANCER DRUGS MARKET RESEARCH PROCESS
• FIGURE 2. THYROID CANCER DRUGS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL THYROID CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
• FIGURE 15. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. AMERICAS THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. AMERICAS THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 19. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. ASIA-PACIFIC THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. ASIA-PACIFIC THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. EUROPE, MIDDLE EAST & AFRICA THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 23. EUROPE, MIDDLE EAST & AFRICA THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 24. THYROID CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 25. THYROID CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. THYROID CANCER DRUGS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL THYROID CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. THYROID CANCER DRUGS MARKET DYNAMICS
• TABLE 7. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY HORMONE THERAPY DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY INTRAVENOUS DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY ORAL DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY ADVANCED-STAGE THYROID CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY EARLY-STAGE THYROID CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY ANAPLASTIC THYROID CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY FOLLICULAR THYROID CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY MEDULLARY THYROID CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY PAPILLARY THYROID CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY ONCOLOGY CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. AMERICAS THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 29. AMERICAS THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 30. AMERICAS THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
• TABLE 31. AMERICAS THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 32. AMERICAS THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 33. AMERICAS THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 34. ARGENTINA THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 35. ARGENTINA THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 36. ARGENTINA THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
• TABLE 37. ARGENTINA THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 38. ARGENTINA THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 39. BRAZIL THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 40. BRAZIL THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 41. BRAZIL THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
• TABLE 42. BRAZIL THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 43. BRAZIL THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 44. CANADA THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 45. CANADA THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 46. CANADA THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
• TABLE 47. CANADA THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 48. CANADA THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 49. MEXICO THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 50. MEXICO THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 51. MEXICO THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
• TABLE 52. MEXICO THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 53. MEXICO THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 54. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 55. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 56. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
• TABLE 57. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 58. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 59. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 60. ASIA-PACIFIC THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 61. ASIA-PACIFIC THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 62. ASIA-PACIFIC THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
• TABLE 63. ASIA-PACIFIC THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 64. ASIA-PACIFIC THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 65. ASIA-PACIFIC THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 66. AUSTRALIA THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 67. AUSTRALIA THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 68. AUSTRALIA THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
• TABLE 69. AUSTRALIA THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 70. AUSTRALIA THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 71. CHINA THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 72. CHINA THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 73. CHINA THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
• TABLE 74. CHINA THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 75. CHINA THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 76. INDIA THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 77. INDIA THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 78. INDIA THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
• TABLE 79. INDIA THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 80. INDIA THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 81. INDONESIA THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 82. INDONESIA THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 83. INDONESIA THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
• TABLE 84. INDONESIA THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 85. INDONESIA THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 86. JAPAN THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 87. JAPAN THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 88. JAPAN THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
• TABLE 89. JAPAN THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 90. JAPAN THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 91. MALAYSIA THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 92. MALAYSIA THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 93. MALAYSIA THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
• TABLE 94. MALAYSIA THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 95. MALAYSIA THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 96. PHILIPPINES THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 97. PHILIPPINES THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 98. PHILIPPINES THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
• TABLE 99. PHILIPPINES THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 100. PHILIPPINES THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 101. SINGAPORE THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 102. SINGAPORE THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 103. SINGAPORE THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
• TABLE 104. SINGAPORE THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 105. SINGAPORE THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 106. SOUTH KOREA THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 107. SOUTH KOREA THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 108. SOUTH KOREA THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
• TABLE 109. SOUTH KOREA THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 110. SOUTH KOREA THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 111. TAIWAN THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 112. TAIWAN THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 113. TAIWAN THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
• TABLE 114. TAIWAN THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 115. TAIWAN THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 116. THAILAND THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 117. THAILAND THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 118. THAILAND THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
• TABLE 119. THAILAND THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 120. THAILAND THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 121. VIETNAM THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 122. VIETNAM THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 123. VIETNAM THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
• TABLE 124. VIETNAM THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 125. VIETNAM THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 126. EUROPE, MIDDLE EAST & AFRICA THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 127. EUROPE, MIDDLE EAST & AFRICA THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 128. EUROPE, MIDDLE EAST & AFRICA THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
• TABLE 129. EUROPE, MIDDLE EAST & AFRICA THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 130. EUROPE, MIDDLE EAST & AFRICA THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 131. EUROPE, MIDDLE EAST & AFRICA THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 132. DENMARK THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 133. DENMARK THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 134. DENMARK THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
• TABLE 135. DENMARK THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 136. DENMARK THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 137. EGYPT THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 138. EGYPT THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 139. EGYPT THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
• TABLE 140. EGYPT THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 141. EGYPT THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 142. FINLAND THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 143. FINLAND THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 144. FINLAND THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
• TABLE 145. FINLAND THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 146. FINLAND THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 147. FRANCE THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 148. FRANCE THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 149. FRANCE THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
• TABLE 150. FRANCE THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 151. FRANCE THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 152. GERMANY THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 153. GERMANY THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 154. GERMANY THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
• TABLE 155. GERMANY THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 156. GERMANY THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 157. ISRAEL THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 158. ISRAEL THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 159. ISRAEL THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
• TABLE 160. ISRAEL THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 161. ISRAEL THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 162. ITALY THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 163. ITALY THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 164. ITALY THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
• TABLE 165. ITALY THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 166. ITALY THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 167. NETHERLANDS THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 168. NETHERLANDS THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 169. NETHERLANDS THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
• TABLE 170. NETHERLANDS THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 171. NETHERLANDS THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 172. NIGERIA THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 173. NIGERIA THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 174. NIGERIA THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
• TABLE 175. NIGERIA THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 176. NIGERIA THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 177. NORWAY THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 178. NORWAY THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 179. NORWAY THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
• TABLE 180. NORWAY THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 181. NORWAY THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 182. POLAND THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 183. POLAND THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 184. POLAND THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
• TABLE 185. POLAND THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 186. POLAND THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 187. QATAR THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 188. QATAR THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 189. QATAR THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
• TABLE 190. QATAR THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 191. QATAR THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 192. RUSSIA THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 193. RUSSIA THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 194. RUSSIA THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
• TABLE 195. RUSSIA THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 196. RUSSIA THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 197. SAUDI ARABIA THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 198. SAUDI ARABIA THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 199. SAUDI ARABIA THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
• TABLE 200. SAUDI ARABIA THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 201. SAUDI ARABIA THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 202. SOUTH AFRICA THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 203. SOUTH AFRICA THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 204. SOUTH AFRICA THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
• TABLE 205. SOUTH AFRICA THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 206. SOUTH AFRICA THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 207. SPAIN THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 208. SPAIN THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 209. SPAIN THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
• TABLE 210. SPAIN THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 211. SPAIN THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 212. SWEDEN THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 213. SWEDEN THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 214. SWEDEN THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
• TABLE 215. SWEDEN THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 216. SWEDEN THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 217. SWITZERLAND THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 218. SWITZERLAND THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 219. SWITZERLAND THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
• TABLE 220. SWITZERLAND THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 221. SWITZERLAND THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 222. TURKEY THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 223. TURKEY THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 224. TURKEY THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
• TABLE 225. TURKEY THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 226. TURKEY THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 227. UNITED ARAB EMIRATES THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 228. UNITED ARAB EMIRATES THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 229. UNITED ARAB EMIRATES THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
• TABLE 230. UNITED ARAB EMIRATES THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 231. UNITED ARAB EMIRATES THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 232. UNITED KINGDOM THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 233. UNITED KINGDOM THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 234. UNITED KINGDOM THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
• TABLE 235. UNITED KINGDOM THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 236. UNITED KINGDOM THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 237. THYROID CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 238. THYROID CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

The Thyroid Cancer Drugs Market was valued at USD 806.01 million in 2023, expected to reach USD 890.96 million in 2024, and is projected to grow at a CAGR of 11.02%, to USD 1,675.77 million by 2030.

The scope of the thyroid cancer drugs market involves pharmaceuticals specifically designed to treat thyroid cancer, including small molecule inhibitors, immunotherapies, radioactive iodine treatment, and thyroid hormone therapy. This sector is crucial for addressing unmet medical needs, as the rising incidence of thyroid cancer emphasizes the necessity for effective treatments. These drugs are applied primarily in clinical settings by healthcare professionals aiming to manage or cure different types of thyroid cancers such as papillary, follicular, medullary, and anaplastic. The end-use scope includes hospitals, oncology centers, and specialized clinics dedicated to cancer treatment. Key growth influencers in this market include advancements in precision medicine and targeted therapies, increasing R&D investments, as well as rising patient awareness and demand for effective treatment options. The emergence of biosimilars and the integration of AI in drug discovery represent potential opportunities, paving the way for more personalized medicine and cost-effective treatments. To capitalize on these opportunities, pharmaceutical companies should invest in robust R&D programs and strategic partnerships to accelerate drug development and streamline regulatory approvals. However, the market faces limitations such as high development costs, stringent regulatory frameworks, and potential side effects associated with thyroid cancer therapies. Additionally, competition from surgical treatment options poses challenges, as some patients opt for surgery over drug-based therapies. In terms of innovation, areas such as the development of novel molecular targets, improvements in drug delivery systems, and the exploration of combination therapies represent significant opportunities for business growth. The market is dynamic but constrained by high competition and regulatory hurdles, which necessitate strategic planning and continuous innovation to maintain competitiveness and secure a foothold in the global market.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Thyroid Cancer Drugs Market

The Thyroid Cancer Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Growing prevalence of thyroid cancer cases across the globe
  • Increasing focus on early diagnosis and treatment
  • Rising private organizations increasing cancer screening programs
• Market Restraints
  • Adverse side effects associated with thyroid cancer treatments
• Market Opportunities
  • Favorable government initiatives promoting cancer awareness and introduction of reimbursement policies
  • Exponential potential for personalized medicine and targeted therapies
• Market Challenges
  • Stringent government drug approval procedures

Porter's Five Forces: A Strategic Tool for Navigating the Thyroid Cancer Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Thyroid Cancer Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Thyroid Cancer Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Thyroid Cancer Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Thyroid Cancer Drugs Market

A detailed market share analysis in the Thyroid Cancer Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Thyroid Cancer Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Thyroid Cancer Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Thyroid Cancer Drugs Market

A strategic analysis of the Thyroid Cancer Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Thyroid Cancer Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Ltd., Aprazer Healthcare Pvt Ltd., AstraZeneca PLC, Bayer AG, Biovista Inc., Bristol Myers Squibb, Dr Reddy's Laboratories Ltd., Eisai Co., Ltd., Eli Lilly and Company, Exelixis Inc., GlaxoSmithKline PLC, Glenmark Pharmaceuticals Ltd., Hetero Healthcare Limited, Loxo Oncology Inc., Lupin Limited, Merck & Co., Inc., MSN Laboratories, Mylan N.V., Natco Pharma Ltd., Novartis AG, Sanofi S.A., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Vascular Biogenics Ltd..

Market Segmentation & Coverage

This research report categorizes the Thyroid Cancer Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Drug Type, market is studied across Chemotherapy Drugs, Hormone Therapy Drugs, Immunotherapy Drugs, and Targeted Therapy Drugs.
• Based on Mode of Administration, market is studied across Injectable Drugs, Intravenous Drugs, and Oral Drugs.
• Based on Stage of Disease, market is studied across Advanced-stage Thyroid Cancer and Early-stage Thyroid Cancer.
• Based on Cancer Type, market is studied across Anaplastic Thyroid Cancer, Follicular Thyroid Cancer, Medullary Thyroid Cancer, and Papillary Thyroid Cancer.
• Based on End User, market is studied across Hospitals, Oncology Clinics, and Research Organizations.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing prevalence of thyroid cancer cases across the globe
    • 5.1.1.2. Increasing focus on early diagnosis and treatment
    • 5.1.1.3. Rising private organizations increasing cancer screening programs
  • 5.1.2. Restraints
    • 5.1.2.1. Adverse side effects associated with thyroid cancer treatments
  • 5.1.3. Opportunities
    • 5.1.3.1. Favorable government initiatives promoting cancer awareness and introduction of reimbursement policies
    • 5.1.3.2. Exponential potential for personalized medicine and targeted therapies
  • 5.1.4. Challenges
    • 5.1.4.1. Stringent government drug approval procedures
• 5.2. Market Segmentation Analysis
  • 5.2.1. Drug Type: Proliferating adoption of the targeted therapy drugs directly translating to better patient outcomes with fewer adverse effects
  • 5.2.2. End User: Evolving utilization of thyroid cancer drugs across the hospitals owing to the advanced facilities
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Thyroid Cancer Drugs Market, by Drug Type

• 6.1. Introduction
• 6.2. Chemotherapy Drugs
• 6.3. Hormone Therapy Drugs
• 6.4. Immunotherapy Drugs
• 6.5. Targeted Therapy Drugs

7. Thyroid Cancer Drugs Market, by Mode of Administration

• 7.1. Introduction
• 7.2. Injectable Drugs
• 7.3. Intravenous Drugs
• 7.4. Oral Drugs

8. Thyroid Cancer Drugs Market, by Stage of Disease

• 8.1. Introduction
• 8.2. Advanced-stage Thyroid Cancer
• 8.3. Early-stage Thyroid Cancer

9. Thyroid Cancer Drugs Market, by Cancer Type

• 9.1. Introduction
• 9.2. Anaplastic Thyroid Cancer
• 9.3. Follicular Thyroid Cancer
• 9.4. Medullary Thyroid Cancer
• 9.5. Papillary Thyroid Cancer

10. Thyroid Cancer Drugs Market, by End User

• 10.1. Introduction
• 10.2. Hospitals
• 10.3. Oncology Clinics
• 10.4. Research Organizations

11. Americas Thyroid Cancer Drugs Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific Thyroid Cancer Drugs Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa Thyroid Cancer Drugs Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. Market Share Analysis, 2023
• 14.2. FPNV Positioning Matrix, 2023
• 14.3. Competitive Scenario Analysis
  • 14.3.1. FDA Approves Selpercatinib for Young Patients with RET-Altered Thyroid Cancer, Expanding Treatment Option
  • 14.3.2. ONO Pharmaceutical Unveils Promising Advances in Thyroid Cancer Treatment
  • 14.3.3. Rigel Pharmaceuticals Secures U.S. Rights to Gavreto, Enhancing Options for Thyroid Cancer Treatment
• 14.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Ltd.
• 2. Aprazer Healthcare Pvt Ltd.
• 3. AstraZeneca PLC
• 4. Bayer AG
• 5. Biovista Inc.
• 6. Bristol Myers Squibb
• 7. Dr Reddy's Laboratories Ltd.
• 8. Eisai Co., Ltd.
• 9. Eli Lilly and Company
• 10. Exelixis Inc.
• 11. GlaxoSmithKline PLC
• 12. Glenmark Pharmaceuticals Ltd.
• 13. Hetero Healthcare Limited
• 14. Loxo Oncology Inc.
• 15. Lupin Limited
• 16. Merck & Co., Inc.
• 17. MSN Laboratories
• 18. Mylan N.V.
• 19. Natco Pharma Ltd.
• 20. Novartis AG
• 21. Sanofi S.A.
• 22. Sun Pharmaceutical Industries Ltd.
• 23. Teva Pharmaceutical Industries Ltd.
• 24. Vascular Biogenics Ltd.